Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Serum CRP levels. (A) Serum CRP levels. T2DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs BTBR. T1DM: n=5 per group. *p<0.001 vs WT; †p<0.001 vs Akita.

Published byIngar Jakobsen Modified over 5 years ago

Similar presentations

Presentation on theme: "(A) Serum CRP levels. (A) Serum CRP levels. T2DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs BTBR. T1DM: n=5 per group. *p<0.001 vs WT; †p<0.001 vs Akita."— Presentation transcript:

1 (A) Serum CRP levels. (A) Serum CRP levels. T2DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs BTBR. T1DM: n=5 per group. *p<0.001 vs WT; †p<0.001 vs Akita. (B) Serum TNFα. T2DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs BTBR. T1DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs Akita. (C) Serum IL-1β T2DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs BTBR. T1DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs Akita. (D) Serum IL-6. T2DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs BTBR. T1DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs Akita. (E) Serum IL-18. T2DM: n=6 per group. *p<0.03 vs WT; †p<0.001 vs BTBR. T1DM: n=6 per group. *p<0.003 vs WT; †p<0.001 vs Akita. CRP, C reactive protein; IL, interleukin; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TNFα, tumor necrosis factor α; WT, wild-type. Yochai Birnbaum et al. BMJ Open Diab Res Care 2016;4:e000227 ©2016 by American Diabetes Association

Download ppt "(A) Serum CRP levels. (A) Serum CRP levels. T2DM: n=6 per group. *p<0.001 vs WT; †p<0.001 vs BTBR. T1DM: n=5 per group. *p<0.001 vs WT; †p<0.001 vs Akita."

Similar presentations

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
(A) Fasting serum glucose (mg/dL), (B) fasting serum insulin (μU/mL), (C) plasma glycated albumin (GA; %) and (D) plasma fructosamine (μmol/L) measured.

(A) Fasting serum glucose (mg/dL), (B) fasting serum insulin (μU/mL), (C) plasma glycated albumin (GA; %) and (D) plasma fructosamine (μmol/L) measured.
Pg and Ec LPS induced levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Pg and Ec LPS induced levels.

Pg and Ec LPS induced levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Pg and Ec LPS induced levels.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.
The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Effect of Ma-Pi diet versus control diet on change in TNF-α, IL-6, CRP, BAP test, and IGF-1. Effect of Ma-Pi diet versus control diet on change in TNF-α,

Effect of Ma-Pi diet versus control diet on change in TNF-α, IL-6, CRP, BAP test, and IGF-1. Effect of Ma-Pi diet versus control diet on change in TNF-α,
Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR
(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p

(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p
Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)

Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Unstimulated levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Unstimulated levels of soluble mediators.

Unstimulated levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Unstimulated levels of soluble mediators.
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.
Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.

Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.
(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Similar presentations

Ads by Google